Although the clinical use of Btk inhibitors has been limited to B-cell malignancies, animal studies have demonstrated the potential efficacy of Btk inhibition in autoimmune diseases, particularly rheumatoid arthritis and SLE (5–10). Here, BTK is linked to systemic lupus erythematosus.